<DOC>
	<DOCNO>NCT01498328</DOCNO>
	<brief_summary>The purpose research study find whether add experimental vaccine call rindopepimut ( also know CDX-110 ) commonly use drug bevacizumab improve progression free survival ( slow growth tumor ) patient relapse EGFRvIII positive glioblastoma .</brief_summary>
	<brief_title>A Study Rindopepimut/GM-CSF Patients With Relapsed EGFRvIII-Positive Glioblastoma</brief_title>
	<detailed_description>This Phase II study enroll patient three group . Group 1 patient never treat bevacizumab . These patient randomly assign receive either rindopepimut/GM-CSF KLH , along bevacizumab . Treatment assignment Group 1 blind . Group 2 Group 2C patient refractory bevacizumab ( experienced recurrence progression glioblastoma bevacizumab within 2 month discontinue bevacizumab ) . These patient receive rindopepimut/GM-CSF along bevacizumab . Patients treat disease progression intolerance patient follow survival . Patients may treat therapy part study discontinue treatment study vaccine .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Among criterion , patient must meet following condition eligible study : 1 . Age ≥18 year age . 2 . Histologic diagnosis glioblastoma ( WHO Grade IV ) . 3 . Documented EGFRvlll positive tumor status ( central lab confirmation ) . 4 . First second relapse de novo glioblastoma first diagnosis first relapse secondary glioblastoma . 5 . Previous treatment must include surgery , conventional radiation therapy temozolomide ( TMZ ) . 6 . Screening MRI must obtain least 4 week salvage surgery , least 12 week radiation therapy . 7 . KPS ≥ 70 % . 8 . If applicable , systemic corticosteroid therapy must dose ≤ 4 mg dexamethasone equivalent per day week prior Day 1 . 9 . Evaluable disease Groups 1 2 ; measurable disease Group 2C 10 . Life expectancy &gt; 12 week . 11 . Patients Group 2 2C must disease progression receive bevacizumab within 2 month treatment bevacizumab . Among criterion , patient meet follow condition NOT eligible study : 1 . Subjects unable undergo MRI contrast . 2 . History , presence , suspicion metastatic disease 3 . Prior receipt vaccination EGFRvIII . 4 . Any known contraindication receipt study drug , include know allergy hypersensitivity keyhole limpet hemocyanin ( KLH ) , GMCSF ( sargramostim ; LEUKINE® ) , polysorbate 80 yeast derived product , history anaphylactic reaction shellfish protein . 5 . Use nonprotein base investigational therapy within 14 day prior Day 1 use antibodybased investigational therapy within 28 day prior Day 1 . 6 . Clinically significant increase intracranial pressure ( e.g. , impending herniation ) , uncontrolled seizure , requirement immediate palliative treatment 7 . Evidence recent hemorrhage screen MRI brain 8 . Evidence current drug alcohol abuse . 9 . Patients Group 1 must receive prior treatment bevacizumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>EGFRvIII</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Rindopepimut</keyword>
	<keyword>CDX-110</keyword>
	<keyword>Small cell</keyword>
	<keyword>Giant cell</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>oligodendroglial</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>Tumor</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Returned</keyword>
	<keyword>Recurrent</keyword>
	<keyword>EGFR variant III</keyword>
</DOC>